In the study of uRCC by Chen et al., NF2 GA also co-occurred with SETD2 and BAP1, and the occurrence of SETD2 mutations was significantly higher in uRCC tumors with NF2 loss than in remaining uRCC tumors (44% vs 9%). The gene discussed is BAP1; the disease is Unclassified Renal Cell Carcinoma.